Protocatechuic acid inhibits rat pheochromocytoma cell damage induced by a dopaminergic neurotoxin

Biological and Pharmaceutical Bulletin

Volumn 32, Issue 11, 2009, Pages 1866-1869

  Zhang, Hong Ning ^a   An, Chun Na ^a   Xu, Man ^b   Guo, De An ^b   Li, Min ^a   Pu, Xiao Ping ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

synuclein; 1 methyl 4 phenylpyridinium ion; Neuroprotection; Protocatechuic acid; Rat pheochromocytoma cell

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ALPHA SYNUCLEIN; NEUROTOXIN; PROTOCATECHUIC ACID; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL STRAIN; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; NEUROPROTECTION; NONHUMAN; OLIGOMERIZATION; PHEOCHROMOCYTOMA CELL; PROTEIN EXPRESSION; RAT;

ALPHA-SYNUCLEIN; ANIMALS; DOPAMINE; HYDROXYBENZOIC ACIDS; NEUROTOXINS; PC12 CELLS; PHEOCHROMOCYTOMA; RATS; TYROSINE 3-MONOOXYGENASE;

EID: 70350731121     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.32.1866     Document Type: Article

References (19)

1. Lev N., Melamed E., Offen D., Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, 245-250 (2003).
2. von Bohlen und Halbach O., Schober A., Krieglstein K., Prog. Neurobiol., 73, 151-177 (2004).
3. Geng X. C., Song L. W., Pu X. P., Tu P. F., Biol. Pharm. Bull., 27, 797-801 (2004).
4. Singha S., Dikshit M., Brain Res. Rev., 54, 233-250 (2007).
5. Toulouse A., Sullivan A. M., Prog. Neurobiol., 85, 376-392 (2008).
6. Yang Y. X., Wood N. W., Latchman D. S., NeuroReport, 20, 150-156 (2009).
7. Sun F., Kanthasamy A., Anantharam V., Kanthasamy A. G., Pharmacol. Ther., 114, 327-344 (2007).
8. Davis G. C., Williams A. C., Markey S. P., Ebert M. H., Caine E. D., Reichert C. M., Kopin I. J., Psychiatry Res., 1, 249-254 (1979).
9. Langston J. W., Ballard P., Tetrud J. W., Irwin I., Science, 219, 979-980 (1983).
10. Chiba K., Trevor A., Castagnoli N. Jr., Biochem. Biophys. Res. Commun., 120, 574-578 (1984).
11. Maguire-Ziss K. A., Pharmacol. Res., 58, 271-280 (2008).
12. Oksman M., Tanila H., Yavich L., Neuropharmacology, 56, 647-652 (2009).
13. Saito S., Kawabata J., Tetrahedron, 61, 8101-8108 (2005).
14. An L. J., Guan S., Shi G. F., Bao Y. M., Duan Y. L., Jiang B., Food Chem. Toxicol., 44, 436-443 (2006).
15. Mutoh T., Tokuda A., Marini A. M., Fujiki N., Brain Res., 661, 51-55 (1994).
16. Nagata K., Takei N., Nakajima K., Saito H., Kohsaka S., J. Neurosci. Res., 34, 357-363 (1993).
17. Xu J., Wei C. Z., Xu C. Q., Bennett M. C., Zhang G. H., Li F. C., Tao E. N., Brain Res., 139, 220-225 (2007).
18. Liu G. W., Zhang C. Y., Yin J. J., Li X., Cheng F. R., Li Y. H., Yang H., Uéda K., Chan P., Yu S., Neurosci. Lett., 454, 187-192 (2009).
19. Banerjee R., Starkov A. A., Beal M. F., Thomas B., Biochim. Biophys. Acta, doi:10.1016/j.bbadis.2008.11.007 (2008).